Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Erosive Esophagitis: early-phase trial registry

3 of 7 indexed Erosive Esophagitis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Erosive Esophagitis: 7 US clinical trials tracked, 3 recruiting.

Erosive Esophagitis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Takeda, running 3 of these trials.

Enrollment posture brief

Registry condition erosive-esophagitis

OPEN 3 | RECR 43% | LATE 2 | EARLY 4 | RANK #2497 | SPON 3

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Erosive Esophagitis (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Erosive Esophagitis

Erosive Esophagitis lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Erosive Esophagitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Erosive Esophagitis is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Erosive Esophagitis research.

    Takeda accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Erosive Esophagitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 76 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Erosive Esophagitis research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1
Phase 4 1

Top Sponsors

Takeda 3 trials
Cinclus Pharma 1 trials
Yvonne Romero 1 trials
AstraZeneca 1 trials

Named interventions

Most-linked intervention names on Erosive Esophagitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dexlansoprazole Drug
3 trials
Lansoprazole Dummy Drug
1 trials
X842 Dummy Drug
1 trials
X842 Drug
1 trials
Lansoprazole Drug
1 trials
Omeprazole/sodium bicarbonate Drug
1 trials
Vonoprazan Drug
1 trials
Nexium 10mg Drug
1 trials

US sites by state

Facility locations filed on Erosive Esophagitis trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Florida 3 trials
California 3 trials
Alabama 3 trials
Texas 2 trials
Tennessee 2 trials
Ohio 2 trials
New York 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Erosive Esophagitis page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Erosive Esophagitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Takeda sponsors the most Erosive Esophagitis trials on record, review their full trial history before evaluating a specific study. See Takeda's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Erosive Esophagitis condition card totals 7 registered trials; most-linked intervention Dexlansoprazole; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.